RIGL NASDAQ
Rigel Pharmaceuticals, Inc.
1W: -2.1%
1M: -4.6%
3M: +17.1%
YTD: +12.7%
1Y: +67.4%
3Y: +324.8%
5Y: +26.1%
$47.15
+0.18 (+0.38%)
Weekly Expected Move ±4.4%
$43
$45
$47
$49
$51
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-11-03
Earliest Filing
2024-09-03
Latest Filing
partner: 4
acquirer: 1
Counterparties (Filed by RIGL)
5 relationshipsCompanies named in RIGL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kissei Pharmaceutical Co., Ltd. | — | partner | Entered into a collaboration and license agreement for exclusive rights to develop and commercialize olutasidenib in Jap | 2024-09-03 | View |
| Forma Therapeutics, Inc. | — | partner | Previously announced an exclusive worldwide license agreement with Rigel for olutasidenib; now part of Novo Nordisk. | 2024-09-03 | View |
| Novo Nordisk | NONOF | partner | Acquired Forma Therapeutics, Inc., which holds rights to olutasidenib sublicensing revenue from Kissei. | 2024-09-03 | View |
| Blueprint Medicines Corporation | — | acquirer | Rigel Pharmaceuticals acquired U.S. rights to pralsetinib from Blueprint Medicines Corporation. | 2024-02-22 | View |
| Atara Biotherapeutics, Inc. | ATRA | partner | Entered into a sublease agreement for office space. | 2022-11-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-07-01 | Officer/Director Change | View | |
| 2026-06-17 | Acquisition/Disposition | Acquisition | View |
| 2026-05-20 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-12 | Material Agreement | Agreement | View |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-21 | Termination of Agreement | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-23 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-27 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-12-09 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR